Contineum Therapeutics (CTNM) Net Cash Flow (2023 - 2026)

Contineum Therapeutics' Net Cash Flow history runs 4 years deep, the most recent figure standing at -$55.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 10620.87% year-over-year to -$55.4 million; the TTM figure through Mar 2026 stood at -$2.3 million (down 137.25% YoY), while the FY2025 annual figure was $53.7 million, up 736.22% from the prior year.
• Net Cash Flow was -$55.4 million for Q1 2026 at Contineum Therapeutics, down from $33.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $61.0 million in Q2 2024 to a low of -$55.4 million in Q1 2026.
• Historically, Net Cash Flow has averaged $1.1 million across 4 years, with a median of $527000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow jumped 274.0% in 2025, then plunged 10620.87% in 2026.
• A 4-year view of Net Cash Flow shows it stood at -$2.0 million in 2023, then slumped by 849.77% to -$18.9 million in 2024, then surged by 274.0% to $33.0 million in 2025, then tumbled by 268.17% to -$55.4 million in 2026.
• The last three Net Cash Flow figures came in at -$55.4 million (Q1 2026), $33.0 million (Q4 2025), and $21.8 million (Q3 2025), per Business Quant data.